cemka > Publications > Cardiologie

Classer les publications sur l'année

  • Pharmaco-EpidĂ©miologie

    Medico-economic comparison of two anticoagulant treatment strategies: Vitamin K antagonists vs. direct oral anticoagulants in older adults in nursing homes in France. The « MIKADO » study

    PISICA-DONOSE G, PICCOLI M, GENET B, BOUEE S, BERECHET S, BERECHET I, DACASA CORTES A, ATSAMENA S, BAYLE C, BADESCU M, CATELAIN F, KERMECHE L, MERLIER I, RAKOTONIARY S, SAVIN V, VIDAL A, VIDAL J-S, HANON O.

    PLoS One  ; 2023;18(4):e0283604

  • SantĂ© Publique et EpidĂ©miologie

    Organisational Impact of a Remote Patient Monitoring System for Heart Failure Management: The Experience of 29 Cardiology Departments in France.

    ALAMI S, COUROUVE L, LANCMAN G, GOMIS P, AL-HAMOUD G, LAURELLI C, PASCHE H, CHATELLIER G, MERCIER G, ROUBILLE F, DELVAL C, DURAND-ZALESKI I.

    Int J Environ Res Public Health ; 2023;20(5):4366

  • Économie de la santĂ©

    A telemonitoring programme in patients with heart failure in France: a cost‑utility analysis

    CAILLON M, SABATIER R, LEGALLOIS D, COUROUVE L, DONIO V, BOUDEVIN F, DE CHALUS T, HAUCHARD K, BELIN A, MILLIEZ P.

    BMC Cardiovascular Disorders ; 2022;22(1):441

  • SantĂ© Publique et EpidĂ©miologie

    Impact of patient engagement in a French telemonitoring programme for heart failure on hospitalization and mortality

    SABATIER R, LEGALLOIS D, JODAR M, COUROUVE L, DONIO V, BOUDEVIN F, DE CHALUS T, HAUCHARD K, BELIN A, MILLIEZ P.

    ESC Heart Failure ; 2022;9(5):2886-2898

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Appariement probabiliste au SystĂšme national des donnĂ©es de santĂ© d’un programme de tĂ©lĂ©surveillance Ă  domicile des patients atteints d’insuffisance cardiaque en Normandie

    COUROUVE L, JODAR M, GABBAS M, LEGALLOIS D, DONIO V, SABATIER R

    Revue d'ÉpidĂ©miologie et de SantĂ© Publique ; 2020;68(supp.1):S39

  • SantĂ© Publique et EpidĂ©miologie

    Cost-effectiveness analysis of a telemonitoring program on patients with heart failure in Normandy: an 8-year retrospective analysis (2009–2017)

    SABATIER R, LEGALLOI DS, JODAR M, DONIO V, COUROUVE L, HAUCHARD K, BOUDEVIN F, DE CHALUS T, BELIN A, MILLIEZ P

    European Heart Journal ; 2020;41(supp.2)

  • Pharmaco-EpidĂ©miologie

    Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation

    HANON O, VIDAL JS, PISICA-DONOSE G, ORVOËN G, DAVID JP, CHAUSSADE E, CAILLARD L, DE JONG LW, BOULLOCHE N, VINSONNEAU U, BOUEE S, KROLAK-SALMON P, FAUCHIER L, JOUANNY P, SACCO G, BELLARBRE F, BELMIN J, PUISIEUX F, LILAMAND M, PAILLAUD E, BOUREAU AS ; SAFIR STUDY GROUP

    Heart ; 2020(Online)

  • SantĂ© Publique et EpidĂ©miologie

    Expérimentation de la télé-expertise en cardiologie en Pays de la Loire.

    HERAULT T, DONIO V, COUROUVE L, CAILLARD J.-B.

    Santé publique ; 2019;31(6):789-796

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.

    EMERY C, TORRETON E, BRIERE JB, THOMAS EVERS T, FAGNANI F.

    J Med Econ ; 2020;23(5):513-520

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)

    PHILIPPE F, BLIN P, BOUÉE S, LAURENDEAU C, TORRETON E, GOURMELIN J, VELKOVSKI-ROUYER M, LEVY-BACHELOT L, STEG G.

    Ann Cardiol Angeiol ; 2017;66(2):74-80

  • Économie de la santĂ©

    Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)

    BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.

    J Med Econ ; 2018; 21(12):1213-1220

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database

    DALLONGEVILLE J, SACHER F, BOUEE S , EMERY C, BUREAU I, GOURMELEN J, FAUCHIER L.

    Therapie ; 2018;73:449-460

  • Économie de la santĂ©

    Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients : A French adaptation of CARDS

    LAFUMA A, COLIN X, SOLESSE A

    Arch Cardiovasc Dis ; 2008;101(5):327-332

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Costs of cardiovascular events of diabetic patients in French hospitals

    COLIN X, LAFUMA A, GUERON B

    Diabetes Metab ; 2007;33(4):310-313

  • Pharmaco-EpidĂ©miologie

    Epidémiologie de la maladie thromboembolique veineuse

    BENARD E, LAFUMA A, RAVAUD P

    Presse Med ; 2005;34(6):415-419